Company profile EYPT
After 39 days of this quarter the interest is at 48.0. Based on that we can calculate that during remaining 52 days it will total up to 112.0. EyePoint Pharmaceuticals expected interest is significantly lower compared to previous quarter (-63.8%) but similar to same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 111 | 138 24.3% QoQ | 186 34.8% QoQ | 81 -56.5% QoQ |
| 2020 | 148 33.3% YoY 82.7% QoQ | 150 8.7% YoY 1.4% QoQ | 125 -32.8% YoY -16.7% QoQ | 81 0.0% YoY -35.2% QoQ |
| 2021 | 139 -6.1% YoY 71.6% QoQ | 41 -72.7% YoY -70.5% QoQ | 47 -62.4% YoY 14.6% QoQ | 70 -13.6% YoY 48.9% QoQ |
| 2022 | 67 -51.8% YoY -4.3% QoQ | 177 331.7% YoY 164.2% QoQ | 87 85.1% YoY -50.8% QoQ | 114 62.9% YoY 31.0% QoQ |
| 2023 | 130 94.0% YoY 14.0% QoQ | 222 25.4% YoY 70.8% QoQ | 204 134.5% YoY -8.1% QoQ | 309 171.1% YoY 51.5% QoQ |
| 2024 | 48 -63.1% YoY -84.5% QoQ | - | - | - |
The average 5 years interest of EyePoint Pharmaceuticals was 10.25 per week. The last year interest of EyePoint Pharmaceuticals compared to the last 5 years has changed by 67.9%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 55.61%.
There is not enough data for EyePoint Pharmaceuticals eye disorders to provide analysis
There is not enough data for EyePoint Pharmaceuticals eye disorders to provide correlation calculation
There is not enough data for EyePoint Pharmaceuticals eye disorders to provide analysis
There is not enough data for EYP-1901 to provide analysis
There is not enough data for EYP-1901 to provide correlation calculation
There is not enough data for EYP-1901 to provide analysis
There is not enough data for EyePoint Pharmaceuticals clinical trials to provide analysis
There is not enough data for EyePoint Pharmaceuticals clinical trials to provide correlation calculation
There is not enough data for EyePoint Pharmaceuticals clinical trials to provide analysis
There is not enough data for EyePoint Pharmaceuticals Durasert E technology to provide analysis
There is not enough data for EyePoint Pharmaceuticals Durasert E technology to provide correlation calculation
There is not enough data for EyePoint Pharmaceuticals Durasert E technology to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. EyePoint Pharmaceuticals news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 100 | 117 17.0% QoQ | 61 -47.9% QoQ | 33 -45.9% QoQ |
| 2020 | 121 21.0% YoY 266.7% QoQ | 286 144.4% YoY 136.4% QoQ | 96 57.4% YoY -66.4% QoQ | 104 215.2% YoY 8.3% QoQ |
| 2021 | 167 38.0% YoY 60.6% QoQ | 85 -70.3% YoY -49.1% QoQ | 114 18.8% YoY 34.1% QoQ | 209 101.0% YoY 83.3% QoQ |
| 2022 | 113 -32.3% YoY -45.9% QoQ | 23 -72.9% YoY -79.6% QoQ | 97 -14.9% YoY 321.7% QoQ | 0 -100.0% YoY -100.0% QoQ |
| 2023 | 208 84.1% YoY inf% QoQ | 99 330.4% YoY -52.4% QoQ | 76 -21.6% YoY -23.2% QoQ | 192 inf% YoY 152.6% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of EyePoint Pharmaceuticals news was 8.82 per week. The last year interest of EyePoint Pharmaceuticals news compared to the last 5 years has changed by 7.48%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 40.86%.
There is not enough data for EyePoint Pharmaceuticals stock price to provide analysis
There is not enough data for EyePoint Pharmaceuticals stock price to provide correlation calculation
There is not enough data for EyePoint Pharmaceuticals stock price to provide analysis
There is not enough data for EyePoint Pharmaceuticals careers to provide analysis
There is not enough data for EyePoint Pharmaceuticals careers to provide correlation calculation
There is not enough data for EyePoint Pharmaceuticals careers to provide analysis
There is not enough data for EyePoint Pharmaceuticals Massachusetts to provide analysis
There is not enough data for EyePoint Pharmaceuticals Massachusetts to provide correlation calculation
There is not enough data for EyePoint Pharmaceuticals Massachusetts to provide analysis
After 39 days of this quarter the interest is at 34.0. Based on that we can calculate that during remaining 52 days it will total up to 79.0. EyePoint Pharmaceuticals -stock -company expected interest is significantly lower compared to previous quarter (-54.1%) and same quarter last year (-47.3%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 94 | 89 -5.3% QoQ | 148 66.3% QoQ | 71 -52.0% QoQ |
| 2020 | 108 14.9% YoY 52.1% QoQ | 53 -40.4% YoY -50.9% QoQ | 153 3.4% YoY 188.7% QoQ | 122 71.8% YoY -20.3% QoQ |
| 2021 | 117 8.3% YoY -4.1% QoQ | 69 30.2% YoY -41.0% QoQ | 43 -71.9% YoY -37.7% QoQ | 103 -15.6% YoY 139.5% QoQ |
| 2022 | 55 -53.0% YoY -46.6% QoQ | 103 49.3% YoY 87.3% QoQ | 111 158.1% YoY 7.8% QoQ | 58 -43.7% YoY -47.7% QoQ |
| 2023 | 150 172.7% YoY 158.6% QoQ | 149 44.7% YoY -0.7% QoQ | 142 27.9% YoY -4.7% QoQ | 172 196.6% YoY 21.1% QoQ |
| 2024 | 34 -77.3% YoY -80.2% QoQ | - | - | - |
The average 5 years interest of EyePoint Pharmaceuticals -stock -company was 8.21 per week. The last year interest of EyePoint Pharmaceuticals -stock -company compared to the last 5 years has changed by 44.09%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 37.56%.